The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases

International Journal of Radiation Oncology Biology Physics

Volumn 96, Issue 2, 2016, Pages 406-413

  Sperduto, Paul W ^a   Yang, T Jonathan ^b   Beal, Kathryn ^b   Pan, Hubert ^c   Brown, Paul D ^c   Bangdiwala, Ananta ^d   Shanley, Ryan ^d   Yeh, Norman ^e   Gaspar, Laurie E ^e   Braunstein, Steve ^f   Sneed, Penny ^f   Boyle, John ^g   Kirkpatrick, John P ^g   Mak, Kimberley S ^h   Shih, Helen A ^h   Engelman, Alex ⁱ   Roberge, David ^j   Arvold, Nils D ^k   Alexander, Brian ^k   Awad, Mark M ^k   Contessa, Joseph ^l   Chiang, Veronica ^l   Hardie, John ^m   Ma, Daniel ^m   Lou, Emil ^a   Sperduto, William ^g   Mehta, Minesh P ⁱ   more..

^a UNIVERSITY OF MINNESOTA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g DUKE UNIVERSITY   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ UNIVERSITY OF MARYLAND   (United States)

^j CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

^l YALE UNIVERSITY   (United States)

^m MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BIOLOGICAL ORGANS; DISEASES; ENZYMES; GENES; PATHOLOGY;

ALTERATION RATES; BRAIN METASTASIS; CANCER MORTALITY; HAZARD RATIO; LUNG CANCER; MEDIAN SURVIVAL; TYROSINE KINASE;

DIAGNOSIS;

CRIZOTINIB; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GENETIC MARKER;

ADULT; ALK GENE; BRAIN METASTASIS; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CAUSE OF DEATH; CONFERENCE PAPER; EGFR GENE; ENZYME INHIBITION; FEMALE; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; MULTICENTER STUDY (TOPIC); ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; RECEPTOR GENE; RETROSPECTIVE STUDY; ADENOCARCINOMA; AGED; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; CLINICAL TRIAL; EPIDEMIOLOGY; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; INCIDENCE; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; PREVALENCE; RISK FACTOR; SECONDARY; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; UNITED STATES; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; PROTEIN-TYROSINE KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 84994491657     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2016.06.006     Document Type: Conference Paper

References (23)

1. 1 Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA Cancer J Clin 65 (2015), 5–29.
2. 2 Villano, J.L., Durbin, E.B., Normandeau, C., et al. Incidence of brain metastasis at initial presentation of lung cancer. Neuro Oncol 17 (2015), 122–128.
3. 3 Nathoo, N., Chahlavi, A., Barnett, G.H., et al. Pathobiology of brain metastases. J Clin Pathol 58 (2005), 237–242.
4. 4 Wen, P.Y., Loeffler, J.S., Brain metastases. Curr Treat Options Oncol 1 (2000), 447–458.
5. 5 Park, D.M., Posner, J.B., Management of intracranial metastases: History. Sawaya, R., (eds.) Intracranial metastases: Current management strategies, 2004, Blackwell Publishing Ltd, Oxford, England, 3–19.
6. 6 Sperduto, P.W., Kased, N., Roberge, D., et al. Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30 (2011), 419–425.
7. 7 Patchell, R.A., Tibbs, P.A., Walsh, J.W., et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322 (1990), 494–500.
8. 8 Patchell, R.A., Tibbs, P.A., Regine, W.F., et al. Postoperative radiotherapy in the treatment of single metastases to the brain. JAMA 280 (1998), 1485–1489.
9. 9 Andrews, D.W., Scott, C.B., Sperduto, P.W., et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363 (2004), 1665–1672.
10. 10 Aoyama, H., Shirato, H., Tago, M., et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA 295 (2006), 2483–2491.
11. 11 Chang, E.L., Wefel, J.S., Hess, K.R., et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomized controlled trial. Lancet Oncol 10 (2009), 1037–1044.
12. 12 Rosell, R., Carcereny, E., Gervais, R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13 (2012), 239–246.
13. 13 Shaw, A.T., Kim, D.W., Nakagawa, K., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368 (2013), 2385–2394.
14. 14 Gaspar, L.E., Scott, C., Rotman, M., et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37 (1997), 745–751.
15. 15 Sperduto, P.W., Chao, S.T., Sneed, P.K., et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: A multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 77 (2010), 655–661.
16. 16 Harris, P.A., Taylor, R., Thielke, R., et al. Research electronic data capture (REDCap): A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42 (2009), 377–381.
17. 17 Heon, S., Yeap, B.Y., Lindeman, N.I., et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res 18 (2012), 4406–4414.
18. 18 Mak, K.S., Gainor, J.F., Niemierko, A., et al. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. Neuro Oncol 17 (2015), 296–302.
19. 19 Johung, K.L., Yeh, N., Desai, N.B., et al. Extended survival and prognostic factors for patients with ALK-rearranged non-small cell lung cancer and brain metastasis. J Clin Oncol 33 (2015), 1–7.
20. 20 Sperduto, P.W., Wang, M., Robins, H.I., et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolamide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 85 (2013), 1312–1318.
21. 21 Sperduto, P.W., Shanley, R., Luo, X., Secondary analysis of RTOG 9508, a phase III randomized trial of whole brain radiation therapy (WBRT) versus WBRT plus stereotactic radiosurgery (SRS) in patients with 1-3 brain metastases; post-stratified by the graded prognostic assessment (GPA). Int J Radiat Oncol Biol Phys 90 (2014), 526–531.
22. 22 Aoyama, H., Tago, M., Shirato, H., Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: Secondary analysis of the JROSG 99-1 randomized clinical trial. JAMA Oncol 1 (2015), 457–464.
23. 23 Nichols, L., Saunders, R., Knollman, F.D., Causes of death of patients with lung cancer. Arch Pathol Lab Med 136 (2012), 1552–1557.